Straits Times Index
3,348.87 +12.28 (+0.37%) S&P 500
5,299.74 +22.23 (+0.42%) Dow
38,658.00 -28.32 (-0.07%) Nasdaq
16,896.53 +161.51 (+0.97%) Bitcoin USD
70,046.85 +2,027.70 (+2.98%) CMC Crypto 200
1,499.91 +31.97 (+2.18%)
HALO Mar 2025 35.000 call
| Previous close | 11.40 |
| Open | 11.40 |
| Bid | 10.00 |
| Ask | 13.90 |
| Strike | 35.00 |
| Expiry date | 2025-03-21 |
| Day's range | 11.40 - 11.40 |
| Contract range | N/A |
| Volume | |
| Open interest | 3 |
ZacksWhy Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
PR NewswireHalozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE®
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Bristol Myers Squibb was reassigned a Prescription Drug User Fee Act goal date from the U.S. Food and Drug Administration for their Biologics License Application for the subcutaneous formulation of Opdivo® (nivolumab) co-formulated with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme, rHuPH20, across all previously approved adult, solid tumor Opdivo indications as monotherapy, monotherapy mainten
ZacksHere's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
